The IP landscape for dual-strip Dry Powder Inhalers is complex, but successful device IP strategies remain available to pharmaceutical companies pursuing this product. Similarly, the Industrial Design of Xaloc is still open to adapt to the design language of its manufacturer. While matching product performance and user sequence of use limits certain aspects of the design, the final product will have distinctive character.
Perdigó has extensive experience in achieving aerosol performance match with respect to an RLD such as Trellegy Ellipta (GSK). Metrics of reference include the NGI profile, several definitions of FPF including ISM, and delivered dose, which may be tested at different airflow rates. We further assess metrics from non-analyical test methods such as delivered mass and PSD.
Human Factors play an integral role in combination product development. For directly substitutable generics (FDA 505j submission route), it is important to show equivalence of the sequence of use, in addition to good usability through the product lifecycle.
To develop a drug delivery device, be it this Xaloc inhaler or any other one, contact us.